Platform-derived programs

About Ophidion

Ophidion is a private, preclinical-stage biotechnology company pioneering a novel CNS carrier technology to noninvasively deliver therapeutics across the blood-brain barrier. Founded in 2018, the company is leveraging its platform to build a pipeline targeting neurodegenerative diseases, a major unmet medical need. The leadership team comprises seasoned pharmaceutical executives with deep experience in neuroscience, drug development, and business strategy, positioning the company to advance its platform and therapeutic programs.

About S. M. Discovery Group (SMDG)

SMDG is a private, pre-clinical stage biotech focused on revolutionizing treatment for neurological and rare diseases through its proprietary targeted delivery platforms. The company's core strength lies in its scientific foundation, led by globally recognized researchers in nanomedicine and drug delivery, which has earned it multiple innovation awards. While still in the discovery and pre-clinical phase, SMDG is positioning itself to address significant market opportunities in areas like neurodegeneration with potentially safer and more precise genetic medicines. Its success hinges on advancing its platform technologies into clinical development and securing strategic partnerships or funding.

Therapeutic Areas